Our findings confirm that FLT3-ITD AML is associated with distinct clinical and molecular characteristics such as higher white blood cell counts, bone marrow blast percentages, and co-occurrence with NPM1 mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.